The US market for Hemostats and Sealants grew +5.8% YoY in Q419, comparable to its +6.2% growth in Q319, with continued strength in fibrin sealants and good growth in absorbable hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market maintained a solid growth rate of +5.8% in Q419 and grew +5.7% YoY. Leading the way in Q419 was Becton Dickinson (BD),  as its relaunch of Progel continued its resurgence. Baxter also posted strong gains.

Among the many topics covered in the comprehensive Q419/FY19 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market showed robust growth in Q419, improving on Q319. Breast matrices rebounded from its Q319 malaise, while hernia matrices grew YoY.

In Q419, the US Surgical Matrices Market grew +8.5% YoY, and was up +4.2% for FY19 according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan broke out of its  Alloderm supply constraints, and Becton Dickinson (BD) also did quite well.

• Q419 Breast Matrices market found its groove again, up YoY. For FY19 Breast Matrices grew well, despite several weak quarters.
• Q419 US Hernia Matrices market increased its growth, with the highest growth rate in biosynthetics and with both xenografts and allografts showing surprising strength. For the year, Hernia Matrices edged up.
• Allergan beat its supply constraints and maintained its leadership of the Breast Matrices market, as Alloderm returned to the market in force. For the full year, Allergan slid due to those Alloderm supply problems.
• BD maintained its No. 1 position in the Q419 Hernia Matrices market.

Among the many topics covered in the comprehensive Q419/FY19 US Surgical Matrices Market Recap* are:

A panel session at ACS Clinical Congress 2019 examines the evidence behind currently proposed techniques to prevent incisional hernias after midline laparotomy closure, including the use of prophylactic mesh and small-bite 4:1 suture closure.

At the American College of Surgeons (ACS) Clinical Congress 2019, there was an important session in which panelists discussed the advantages and disadvantages of using prophylactic mesh after closure of midline laparotomies to prevent incisional hernias. Ajita Prabhu, MD and Benjamin Poulose, MD moderated the panel session on October 28, 2019.

Heidi Miller, MD of University of New Mexico gave background on risk factors for incisional hernias, which she estimated at 12-13% incidence after closure of a laparotomy. She characterized incisional hernias as “mostly due to technical failures,” including poor wound hemostasis or coagulopathy, too much inflammation of the wound and the associated abnormal collagen structure, and sutures without proper tension. With respect to the latter topic, she described how she likes to view the hernia as a chronic wound, with proliferation and remodeling dependent on proper tension of approximation. She also described modifiable risk factors associated with the patient. Smoking and diabetes affect tissue perfusion, with strong data supporting tissue ischemia associated with smoking. Tissue perfusion greatly affects wound healing, as do modifiable factors that affect inflammation, including proper wound care, nutrition (especially vitamin A intake) and obesity, which is associated with chronic inflammation. Additionally, obesity is also associated with increased risk of wound dehiscence and increased mechanical stress tending to open the wound ...

The US market for Hemostats and Sealants grew +5.6% YoY in Q319, a continued deceleration from +6.4% YoY in Q219, with fibrin sealants and absorbable hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market experienced revenue growth in Q319. Leading the way was Becton Dickinson (BD), with Integra, Ethicon and Baxter all posting strong gains. The US Hemostats and Sealants market was up +5.6% YoY with all competitors posting gains for the quarter. Sealants continued their solid growth, up +6.5% YoY, with fibrin sealants leading the way. Absorbable hemostats resumed their leadership, contributing to the +5.1% YoY growth to...

Among the many topics covered in the complete, comprehensiveQ319 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market grew tepidly in Q319,  up +1.2% YoY,  down from its +3.5% growth in Q219. 

The overall US Surgical Matrices market had minimal growth for the quarter at +1.2% YoY, a decline from Q219. The Breast segment contracted -1.5% YoY and a 34.7% share of the entire Surgical Matrices market. The Hernia Repair market continued its modest growth at +2.6% YoY and a 65.3% share of the US Surgical Matrices Market in Q319.

In Q319, Allergan’s hold on the Breast Matrices segment slipped further due to supply chain issues with its AlloDerm ADM, but the Company maintained its leadership of the Surgical Matrices market a 32.3% share. BD continued its growth in their biosynthetic hernia matrices business and maintained No. 2 market position, with revenues of ...

The US market for Hemostats and Sealants grew +6.4% YoY in Q219, a slightly lower growth rate vs Q119, with biologic sealants and thrombin hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the US Hemostats and Sealants market, except Ethicon, experienced revenue growth in Q219. Leading the way was Baxter, as it capitalized on Ethicon’s supply problems with Surgiflo. Cryolife and Becton Dickinson (BD) both posted strong gains. Ethicon still continued to dominate the overall US Hemostat and Sealants market, with a 40.7% share, down from 48.6% share in Q119. Most of this share shifted to Baxter as the Company continues to chip away at...

Among the many topics covered in the Q219 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market continued its modest growth in Q219, with growth in breast matrices continuing to outpace hernia matrices.

SmartTRAK reports that the US Surgical Matrices market, comprised of matrices used for Breast Reconstruction and Hernia Repair, experienced single digit growth in Q219 according to SmartTRAK estimates. The fast-growing Breast Reconstruction segment slowed to +4.6% YoY during the quarter, while the US Hernia Repair market ticked up slightly to +2.9% YoY.

Among the many topics covered in the Q219 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

The US Surgical Matrices Market continued to advance in Q418, driven by a resurgence of Becton Dickinson in hernia matrices and continued growth of breast matrices.  The US market grew +9.7% in FY18.

SmartTRAK reports that the US Surgical Matrices market grew in both the Breast and Hernia Repair segments. SmartTRAK estimates the Breast segment grew again at +21.8% YoY growth to 35.2% share of the entire Surgical Matrices market. The Hernia Repair market continued its recovery up +4.8% YoY and 64.8% share of the US Surgical Matrices Market in Q418.  

Among the many topics covered in the Q418/FY18 Surgical Matrices Market Recap are:

Doug Devens, SmartTRAK's Senior Analyst, Biosurgery wrote a fascinating article titled "Growth Amid Debate: Open vs Robotic Techniques for Inguinal Hernia Repair", in which he shines a light on issues and trends in robotic surgery and the market for inguinal hernia matrices.